Hysterectomy, even with ovarian conservation, is associated with an increased long-term risk for de novo depression.
Researchers sought to determine patient and visit characteristics associated with the discussion of postmenopausal vulvovaginal symptoms at well-woman examinations.
Researchers sought to assess the ability of the Fracture Risk Assessment Tool to discriminate between women who do and do not experience major osteoporotic fractures.
Frequent or persistent vasomotor symptoms during the menopause transition are associated with increased risk for later cardiovascular disease events.
Higher estradiol doses had significant benefits for cardiovascular risk factors in early postmenopausal women, but these effects were attenuated in late postmenopausal women.
The neurokinin 3 receptor antagonist fezolinetant reduces the frequency and severity of vasomotor symptoms in menopause.
The menopausal transition may be a stronger determinant of serum cardiovascular risk factors than chronologic age.
Follicle-stimulating hormone levels may independently predict ongoing or imminent bone loss during the menopausal transition.
For women aged 50 to 59 years with a history of bilateral oophorectomy, estrogen therapy may have beneficial effects in the long-term.
Although use of hormone therapy can have some protective effect on muscle mass in postmenopausal women, the benefit is small in the general population.
Use of menopausal hormonal therapy for 5 years around the start of menopause may be associated with increased risk for breast cancer.